<DOC>
	<DOC>NCT00329693</DOC>
	<brief_summary>Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.</brief_summary>
	<brief_title>Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide</brief_title>
	<detailed_description>No data to be entered.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Quinagolide</mesh_term>
	<criteria>Inclusion Criteria 1. Signed Informed Consent Form, prior to screening evaluations 2. In good physical and mental health 3. Premenopausal females between the ages of 2137 years (both inclusive) at the time of randomisation 4. Infertility for at least 1 year before randomisation, except for proven bilateral tubal infertility Exclusion Criteria 1. Any clinically significant systemic disease 2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) 3. History of recurrent miscarriage 4. Undiagnosed vaginal bleeding</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>